866-997-4948(US-Canada Toll Free)

Diabetic Neuropathy - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 114 Pages

Diabetic Neuropathy - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2017, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 4, 17 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Neuropathy - Overview 9
Diabetic Neuropathy - Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 17
Diabetic Neuropathy - Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 21
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Diabetic Neuropathy - Companies Involved in Therapeutics Development 28
Achelios Therapeutics Inc 28
Angelini Group 28
Apollo Endosurgery Inc 28
Araim Pharmaceuticals Inc 29
Arena Pharmaceuticals Inc 29
Bristol-Myers Squibb Co 30
Celgene Corp 30
Commence Bio Inc 31
Grifols SA 31
Grunenthal GmbH 31
Immune Pharmaceuticals Inc 32
Kineta Inc 32
KPI Therapeutics Inc 32
Medifron DBT Co Ltd 33
Mitsubishi Tanabe Pharma Corp 33
Neuralstem Inc 34
NovaLead Pharma Pvt Ltd 34
Novaremed Ltd 34
Omeros Corp 35
Reata Pharmaceuticals Inc 35
Relief Therapeutics Holding AG 36
ViroMed Co Ltd 36
Diabetic Neuropathy - Drug Profiles 38
(amitriptyline + ketamine hydrochloride) - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
(diclofenac sodium + triclocarban) - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
A-100 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
AAD-2004 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
APD-371 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
atexakin alfa - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
BMS-002 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
BNV-222 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
cibinetide - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
CMB-200 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
CNV-2197944 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Cyndacel-M - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
immune globulin (human) - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
KCP-400 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
ketoprofen - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
KU-32 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Lpathomab - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
MDR-16523 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
MDR-652 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
MT-8554 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
NLP-198 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
NRD-135SE1 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
NSI-189 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
PDA-002 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
pirenzepine hydrochloride - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
RTA-901 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Small Molecules for CNS Disorders, Toxicology and Metabolic Disorders - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Small Molecules for Diabetic Neuropathy - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Small Molecules for Pain - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
sodium nitrite SR - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
trazodone hydrochloride - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
U-2902 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
VM-202 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
XK-568b - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
Diabetic Neuropathy - Dormant Projects 102
Diabetic Neuropathy - Discontinued Products 105
Diabetic Neuropathy - Product Development Milestones 106
Featured News & Press Releases 106
Sep 25, 2017: ViroMed, Gene Therapy Powerhouse on Global Stage 106
Aug 02, 2017: Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy 106
Sep 08, 2016: ViroMed proceeding with the Worlds first phase III gene therapy clinical trial for diabetic peripheral neuropathy 107
Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy 108
Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 108
Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 110
Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial 110
Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy 111
Feb 07, 2008: EpiCept Announces Encouraging Results Of Phase II Trial For NP-1 Cream In Diabetic Peripheral Neuropathy 111
Dec 03, 2007: Patient Enrollment Gets Completed In Phase IIb Trial Of EpiCept NP-1 In Diabetic Peripheral Neuropathy 112
Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 113
Disclaimer 114

List of Tables
Number of Products under Development for Diabetic Neuropathy, H2 2017 10
Number of Products under Development by Companies, H2 2017 12
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13
Number of Products under Development by Universities/Institutes, H2 2017 14
Products under Development by Companies, H2 2017 15
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16
Products under Development by Universities/Institutes, H2 2017 17
Number of Products by Stage and Target, H2 2017 19
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 20
Number of Products by Stage and Mechanism of Action, H2 2017 22
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 23
Number of Products by Stage and Route of Administration, H2 2017 25
Number of Products by Stage and Molecule Type, H2 2017 27
Diabetic Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2017 28
Diabetic Neuropathy - Pipeline by Angelini Group, H2 2017 28
Diabetic Neuropathy - Pipeline by Apollo Endosurgery Inc, H2 2017 29
Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals Inc, H2 2017 29
Diabetic Neuropathy - Pipeline by Arena Pharmaceuticals Inc, H2 2017 29
Diabetic Neuropathy - Pipeline by Bristol-Myers Squibb Co, H2 2017 30
Diabetic Neuropathy - Pipeline by Celgene Corp, H2 2017 30
Diabetic Neuropathy - Pipeline by Commence Bio Inc, H2 2017 31
Diabetic Neuropathy - Pipeline by Grifols SA, H2 2017 31
Diabetic Neuropathy - Pipeline by Grunenthal GmbH, H2 2017 32
Diabetic Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H2 2017 32
Diabetic Neuropathy - Pipeline by Kineta Inc, H2 2017 32
Diabetic Neuropathy - Pipeline by KPI Therapeutics Inc, H2 2017 33
Diabetic Neuropathy - Pipeline by Medifron DBT Co Ltd, H2 2017 33
Diabetic Neuropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 34
Diabetic Neuropathy - Pipeline by Neuralstem Inc, H2 2017 34
Diabetic Neuropathy - Pipeline by NovaLead Pharma Pvt Ltd, H2 2017 34
Diabetic Neuropathy - Pipeline by Novaremed Ltd, H2 2017 35
Diabetic Neuropathy - Pipeline by Omeros Corp, H2 2017 35
Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals Inc, H2 2017 36
Diabetic Neuropathy - Pipeline by Relief Therapeutics Holding AG, H2 2017 36
Diabetic Neuropathy - Pipeline by ViroMed Co Ltd, H2 2017 37
Diabetic Neuropathy - Dormant Projects, H2 2017 102
Diabetic Neuropathy - Dormant Projects, H2 2017 (Contd..1), H2 2017 103
Diabetic Neuropathy - Dormant Projects, H2 2017 (Contd..2), H2 2017 104
Diabetic Neuropathy - Discontinued Products, H2 2017 105

List of Figures
Number of Products under Development for Diabetic Neuropathy, H2 2017 10
Number of Products under Development by Companies, H2 2017 11
Number of Products by Top 10 Targets, H2 2017 18
Number of Products by Stage and Top 10 Targets, H2 2017 18
Number of Products by Top 10 Mechanism of Actions, H2 2017 21
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 21
Number of Products by Routes of Administration, H2 2017 24
Number of Products by Stage and Routes of Administration, H2 2017 24
Number of Products by Molecule Types, H2 2017 26
Number of Products by Stage and Molecule Types, H2 2017 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *